FDA Approves Inflectra, Biosimilar to Remicade

The FDA has approved the second U.S. biosimilar, Inflectra (infliximab-dyyb, Celltrion/Hospira/Pfizer), for all eligible indications of the reference product, Remicade (Janssen), but the new agent did not receive the designation for interchangeability.

• adults and children (aged 6 years and older) with moderate to severe Crohn’s disease who have had an